Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 11:04 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 976 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Endothelial Clear all

Conditions: Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
Interventions: AR-13503 Implant 10.6 Dose, AR-13503 Implant 21.2 Dose, AR-13503 42.4 Dose, AR-13503 63.6 Dose; Drug
Lead sponsor: Aerie Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 6
States / cities: Gilbert, Arizona • Beverly Hills, California • Walnut Creek, California + 3 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Quercetin, Acarbose, placebo; Dietary Supplement · Drug
Lead sponsor: Bastyr University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Obesity, Endothelial Dysfunction, Vitamin D Deficiency
Interventions: Vitamin D3; Dietary Supplement
Lead sponsor: Mayo Clinic; Other
Eligibility: 12 Years to 18 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Fuchs' Endothelial Dystrophy
Interventions: DSAEK with graft shaping and smoothing, Standard DSAEK; Procedure
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Healthy, Smokers, Asthma
Interventions: Whole Body Periodic Acceleration (WBPA), Sham WBPA; Device
Lead sponsor: University of Miami; Other
Eligibility: 20 Years to 65 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Peripheral Arterial Disease
Interventions: L-N^G monomethyl arginine (L-NMMA); Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Advanced Solid Tumor
Interventions: BNT326, Pumitamig, Itraconazole, Paroxetine; Drug
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older
Enrollment: 1,438 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 19
States / cities: Phoenix, Arizona • San Francisco, California • Hartford, Connecticut + 15 more

Conditions: Hypertension, Cardiovascular Diseases, Vascular Diseases
Interventions: 25 g of Freeze-dried Strawberry Powder, 50 g of Freeze-dried Strawberry Powder, Placebo Powder; Dietary Supplement
Lead sponsor: Florida State University; Other
Eligibility: 45 Years to 65 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Tallahassee, Florida

Conditions: Type 2 Diabetes, Impaired Renal Function
Interventions: Linagliptin, Placebo; Drug
Lead sponsor: George Washington University; Other
Eligibility: 30 Years to 70 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Prehypertension, Hypertension, Overweight and Obesity, Elevated Blood Pressure, Endothelial Dysfunction, Vascular Stiffness, Sleep
Interventions: Cardiovascular Assessments, Actigraphy, Laboratory assessments, Emotional/Behavioral Assessments; Diagnostic Test
Lead sponsor: Johns Hopkins University; Other
Eligibility: Up to 22 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cardiovascular Disease
Interventions: N-acetylcysteine, Placebo; Drug
Lead sponsor: Boston University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Lymphedema
Interventions: Pazopanib; Drug
Lead sponsor: Kathy Miller; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Rheumatoid Arthritis
Interventions: Not listed
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2020
U.S. locations: 2
States / cities: Dallas, Texas

Conditions: Blood Sugar, Endothelial Function
Interventions: PEAK ATP® with GlycoCarn®, PEAK ATP®, GlycoCarn®, Placebo; Dietary Supplement · Other
Lead sponsor: Supplement Formulators, Inc.; Industry
Eligibility: 25 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Fort Lauderdale, Florida

Conditions: Obesity, Prehypertension, Hypertension
Interventions: Clonidine, Hydrochlorothiazide, Placebo; Drug
Lead sponsor: Gary L. Pierce; Other
Eligibility: 18 Years to 79 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Sedentary Lifestyle
Interventions: Frequent sit-to-stands, Walking breaks, Stand more; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 55 Years and older · Female only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: La Jolla, California

Conditions: HIV
Interventions: Atazanavir, Placebo; Drug · Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 45 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetes, Cardiovascular Diseases, Prediabetes
Interventions: Apple, Placebo; Dietary Supplement
Lead sponsor: Florida State University; Other
Eligibility: 45 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Tallahassee, Florida

Conditions: Coronary Artery Disease
Interventions: Egg supplementation, Egg substitute, Control diet; Dietary Supplement
Lead sponsor: Griffin Hospital; Other
Eligibility: 35 Years to 75 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Derby, Connecticut

Conditions: Fuchs' Endothelial Dystrophy, Fuchs Dystrophy, Fuchs
Interventions: TTHX1114(NM141); Drug
Lead sponsor: Trefoil Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 11
States / cities: Long Beach, California • Petaluma, California • Deerfield Beach, Florida + 8 more

Conditions: Cardiovascular Outcome, Overweight and Obese Women, Perimenopausal Women, Vasomotor Symptoms (VMS)
Interventions: Pork Diet, Plant Diet; Behavioral
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 40 Years to 55 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Macular Degeneration
Interventions: ranibizumab, aflibercept injection (VEGF Trap-Eye, BAY86-5321); Biological
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 50 Years and older
Enrollment: 1,217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 176
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 144 more

Conditions: Coronary Artery Disease
Interventions: Cranberry juice; Dietary Supplement
Lead sponsor: Boston University; Other
Eligibility: 21 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, Wet AMD, CNV, Neovascular AMD, Neovascular Age-related Macular Degeneration, Choroidal Neovascularization
Interventions: ABBV-RGX-314, Ranibizumab (LUCENTIS®); Genetic · Biological
Lead sponsor: AbbVie; Industry
Eligibility: 50 Years to 89 Years
Enrollment: 671 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 89
States / cities: Phoenix, Arizona • Sun City, Arizona • Little Rock, Arkansas + 77 more

Search by objective public record fields.

A Study Assessing AR-13503 Implant in Subjects With nAMD or DME

Effects of Quercetin on Blood Sugar and Blood Vessel Function in Type 2 Diabetes.

Effect of Vitamin D Supplementation on Endothelial Function in Obese Adolescents

OCT-guided DSAEK Graft Shaping and Smoothing

Effect of Whole Body Periodic Acceleration on Airway Endothelial Function

Endothelial Function in Lower Extremity Bypass Grafts

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

The Effects of Strawberries on Blood Pressure in Postmenopausal Women

Linagliptin's Effect on CD34+ Stem Cells

Be-HealthY: Behavioral Risk Factors for Poor Vascular Health in Youth

ROS Signaling in Endothelial Function

A Study of Vascular Endothelial Growth Factor (VEGF) Inhibition in Patients With Unilateral Upper Extremity Lymphedema Following Treatment for Cancer

Study of Venous Endothelial Cells in Rheumatoid Arthritis

Comparing Blood Sugar Levels and Endothelial Function of PEAK ATP® With GlycoCarn®, PEAK ATP® and GlycoCarn® Supplements

Vascular Dysfunction in Human Obesity Hypertension

Sedentary Behavior Interrupted - A Pilot Study of Acute Interventions on Prolonged Sitting

Atazanavir and Endothelial Function in Older HIV Patients

The Effects of Apple Consumption on Cardiovascular Health in Prediabetics and Type 2 Diabetics

Effects of Egg Ingestion on Endothelial Function in Adults With Coronary Artery Disease

TTHX1114(NM141) in Combination With DWEK/DSO

Impact of Lean Pork on Endothelial Function in Perimenopause

Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)

Effect of Cranberry Juice on Endothelial Function

Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD